Summary
The development of treatment forms for bladder outflow obstruction resulting from benign prostatic hyperplasia is traced from the early surgical techniques to the present. The positive effects and the drawbacks of modern pharmacological treatment are weighed against each other.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anderson KM, Liao S (1968) Selective retention of dehydrotestosterone by prostate nuclei. Nature 219:277–279
Barrack ER, Bujnovsky P, Walsh PC (1983) Subcellular distribution of androgen receptors in human normal, benign hyperplastic and malignant prostatic tissues: characterisation of nuclear salt-resistant receptors. Cancer Res 43:1107–1116
Baulieu EE, Lasnitzki I, Robel P (1968) Metabolism of testosterone and action of metabolites on prostate glands grown in organ culture. Nature 219:1155–1156
Bosch RJ, Griffiths DJ, Blom J, Schroeder FH (1989) Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters. J Urol 141:68–72
Brooks JR, Baptista EM, Berman C, Ham EA, Hutchins M, Johnson D, Prumka R, Rasmisson GH, Reynolds GF, Schmitt S, Arth GF (1981) Response of rate ventral prostate to a new and novel 5-alpha reductase inhibitor. Endocrinology 109:830–836
Brooks JR, Berman D, Glitza MS, Gordon LR, Prumka RL, Reynolds GF, Rasmisson GH (1982) Effect of a new 5-alpha reductase inhibitor on size and histological characteristics and androgen concentrations of the canine prostate. Prostate 3:35–44
Bruckovsky N, Wilson JD (1968) The conversion of testosterone to 5-alpha adrostan M-beta-ol-d-one by rat prostate in vitro and in vivo. J Biol Chem 243:2012–2021
Cabot AT (1896) The question of castration for enlarged prostate. Ann Surg 24:265–301
Caine M, Perlberg S, Gordon R (1975) The treatment of benign prostatic hypertrophy with flutamide: a placebo controlled study. J Urol 114:564–568
Champault G, Patel JC, Bonnard AM (1984) A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol 18:461–462
Farnsworth WE, Brown JR (1963) Testosterone metabolism in the prostate. Natl Cancer Inst Monogr 12:323–325
Geller J, Bora R, Roberts T, Newman H, Lin a, Silva R (1965) The treatment of benign prostatic hypertrophy and hypoxyprogesterone caproate. Effect on clinical symptoms, morphology and endocrine function. JAMA 193:121–128
Gklyama T, Yachika S, Iguchi M, Kohri K, Kenoka S, Matsuura T, Nagai N, Kurita T (1983) Clinical studies, uroflowmetric and ultrasonographic evaluation of oxendolone on benign prostatic hypertrophy. Acta Urol Jpn 25:535–536
Huggins C, Stevens RA (1940) The effect of castration on benign hypertrophy of the prostate in man. J Urol 43:705–714
Imperato McGinley J, Guevro L, Gauteri T, Petersen RE (1974) Steroid 5-alpha reductase deficiency in man: an inherited form of pseudohermaphroditism. Science 186:1213–1215
Kaufman J, Goodwin WE (1959) Hormonal management of the benign obstructing prostate: use of combined androgen — oestrogen therapy. J Urol 81:165–171
Peirson EL (1946) A study of the effect of stilboestrol therapy on the size of the benignly enlarged prostate gland. J Urol 55:73–78
Peters CA, Walsh PC (1987) The effect of nafarelin acetate, a luteinizing hormone releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med 317:599–604
Rasmusson GH, Reynolds GF, Utre T, Johnson RB, Prumka RL, Berman C, Brooks JR (1984) Azasteroids as inhibitors of rat prostatic 5-alpha reductase. J Med Chem 27:1690–1701
Reece-Smith H, Marnon A, Smart CJ, Dewsbury K (1986) The value of permixon in benign prostatic hypertrophy. Br J Urol 58:36–40
Scott WW, Wade JC (1969) Medical treatment of benign nodular hyperplasia with cyproterone acetate. J Urol 101:81–85
Shimazaki J, Kurihara H, Ho Y, Shida K (1965) Metabolism of testosterone in the prostate. Gunma J Med Sci 14:313–333
Siiteri PK, Wilson JD (1970) Dihydrotestosterone in prostatic hypertrophy. J Clin Invest 49:1737–1745
Stenger A, Tarayre JP, Cavilla E, Delhon A, Charveron M, Morre M, Lauressergues H (1982) Etude pharmatologique et biochimique de l'extrait hexanique de Serenoa repens B. Gaz Med Fr 89:2041–2048
Sultan C, Terraza A, Devillier C, Cavilla E, Briley M, Loire C, Descomps B (1984) Inhibition of androgen metabolism and binding by a liposterolic extract of Serenoa repens B in human foreskin fibroblasta. J Steroid Biochem 20:515–519
Vermeulen A, Giagulli VA, Scheppe P, Buntinx A, Stoner E (1989) Hormonal effects of an orally active 4-azasteroid inhibitor of 5-alpha reductase in humans. Prostate 14:45–53
Walsh PC, Hutchins AM, Ewing LL (1983) Tissue content of dihydrotestosterone in human prostatic hyperplasia is not supra-normal. J Clin Invest 72:1772–1777
Wolf H, Madson P (1968) Treatment of benign prostatic hypertrophy with progestational agents: a preliminary report. J Urol 99:980–985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kirby, R.S., Christmas, T. The potential value of 5-alpha-reductase inhibition in the treatment of bladder outflow obstruction due to benign prostatic hyperplasia. World J Urol 9, 41–44 (1991). https://doi.org/10.1007/BF00184713
Issue Date:
DOI: https://doi.org/10.1007/BF00184713